Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tong Luo Hua Shi Capsules
- Development stage
- Phase 2
- Lead developer
- First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
- Administration
- Oral
01
Overview
Tong Luo Hua Shi Capsules is a Traditional Chinese Medicine (TCM) botanical product developed by The First Teaching Hospital of Tianjin University of Traditional Chinese Medicine for the treatment of rheumatoid arthritis. In TCM theory, the formulation is intended to 'unblock collaterals' (Tong Luo) and 'resolve dampness' (Hua Shi), addressing the underlying 'Bi syndrome' associated with joint inflammation and pain. It has been evaluated in Phase II clinical trials in China, both as a standalone treatment and alongside conventional therapies such as leflunomide and diclofenac.
- Other names
- Tongluo Huashi Capsules
Beyond the preview
Go deeper on Tong Luo Hua Shi Capsules.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tong Luo Hua Shi Capsules.